J. Sellarés, D. G. Freitas, . De, M. Mengel, J. Reeve et al., Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence, Am J Transplant, vol.12, issue.2, pp.388-99, 2012.

E. Pouliquen, A. Koenig, C. C. Chen, A. Sicard, M. Rabeyrin et al., Recent advances in renal transplantation: antibody-mediated rejection takes center stage, vol.7, p.51, 1000.

L. Meur, Y. Aulagnon, F. Bertrand, D. Heng, A. E. Lavaud et al., Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.16, issue.7, pp.2181-2187, 2016.

D. Bertrand, L. Cheddani, E. I. François, A. Hanoy, M. Laurent et al., Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.17, issue.11, pp.2937-2981, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02316792

C. Leibler, M. Matignon, A. Moktefi, C. Samson, A. Zarour et al., Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR), Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.19, issue.3, pp.894-906, 2019.

E. J. Kim, J. Kwun, A. C. Gibby, J. J. Hong, A. B. Farris et al., Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.14, issue.1, pp.59-69, 2014.

R. A. Bray, H. M. Gebel, R. Townsend, M. E. Roberts, M. Polinsky et al.,

, Posttransplant reduction in preexisting donor-specific antibody levels after belatacept-versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT

, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.18, issue.7, pp.1774-82, 2018.

A. Loupy, M. Haas, C. Roufosse, M. Naesens, B. Adam et al., The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell-and antibody-mediated rejection, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, 2020.

L. Rostaing, P. Massari, V. D. Garcia, E. Mancilla-urrea, G. Nainan et al., Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study, Clin J Am Soc Nephrol CJASN, vol.6, issue.2, pp.430-439, 2011.

M. Froissart, J. Rossert, C. Jacquot, M. Paillard, and P. Houillier, Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function, J Am Soc Nephrol JASN, vol.16, issue.3, pp.763-73, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00149221

S. Mauiyyedi, P. D. Pelle, S. Saidman, A. B. Collins, M. Pascual et al., Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries, J Am Soc Nephrol JASN, vol.12, issue.3, pp.574-82, 2001.

M. Willicombe, P. Brookes, R. Sergeant, E. Santos-nunez, C. Steggar et al.,

, De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy, Transplant J, vol.94, issue.2, pp.172-179, 2012.

A. Loupy and C. Lefaucheur, Antibody-Mediated Rejection of Solid-Organ Allografts, N Engl J Med, vol.379, issue.12, pp.1150-60, 201820.

G. S. Hill, D. Nochy, P. Bruneval, J. P. Duong-van-huyen, D. Glotz et al.,

, Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation, J Am Soc Nephrol JASN, vol.22, issue.5, pp.975-83, 2011.

J. M. Gloor, F. G. Cosio, D. J. Rea, H. M. Wadei, J. L. Winters et al., Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.6, issue.8, pp.1841-1848, 2006.

E. J. Filippone, P. A. Mccue, and J. L. Farber, Transplant glomerulopathy, Mod Pathol Off J U S Can Acad Pathol Inc, vol.31, issue.2, pp.235-52, 2018.

M. Haas, The relationship between pathologic lesions of active and chronic antibodymediated rejection in renal allografts, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.18, issue.12, pp.2849-56, 2018.

D. Viglietti, A. Loupy, A. O. Bestard, O. , D. Van-huyen et al.,

, Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection, J Am Soc Nephrol JASN, vol.29, issue.2, pp.606-625, 2018.

J. Lesage, R. Noël, I. Lapointe, I. Côté, E. Wagner et al., Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy, Transplantation, vol.99, issue.1, pp.69-76, 2015.

P. Patri, S. V. Seshan, M. Matignon, D. Desvaux, J. R. Lee et al., Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy, Kidney Int, vol.89, issue.2, pp.450-458, 2016.

S. S. Wan, T. D. Ying, K. Wyburn, D. M. Roberts, M. Wyld et al., The Treatment of
URL : https://hal.archives-ouvertes.fr/hal-02190980

, Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation, vol.102, issue.4, pp.557-68, 2018.

F. Moreso, M. Crespo, J. C. Ruiz, A. Torres, A. Gutierrez-dalmau et al., Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.18, issue.4, pp.927-962, 2018.

F. Eskandary, H. Regele, L. Baumann, G. Bond, N. Kozakowski et al.,

, Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection, J Am Soc Nephrol JASN, vol.29, issue.2, pp.591-605, 2018.

C. A. Schinstock, R. B. Mannon, K. Budde, A. S. Chong, M. Haas et al.,

, Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group, Transplantation, vol.104, issue.5, pp.911-933, 2020.

F. Vincenti, L. Rostaing, J. Grinyo, K. Rice, S. Steinberg et al., Belatacept and Long-Term Outcomes in Kidney Transplantation, N Engl J Med, vol.374, issue.4, pp.333-376, 2016.

C. Leibler, A. Thiolat, C. Hénique, C. Samson, C. Pilon et al., Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk, J Am Soc Nephrol JASN, vol.29, issue.3, pp.1049-62, 2018.

C. Leibler, A. Thiolat, R. A. Elsner, K. E. Karoui, C. Samson et al., Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives, Kidney Int, vol.95, issue.4, pp.774-86, 2019.

S. Sethi, R. Najjar, A. Peng, J. Choi, K. Lim et al., Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years, Clin Exp Immunol, vol.104, issue.7, pp.250-61, 2019.

O. Aubert, A. Loupy, L. Hidalgo, J. Duong-van-huyen, S. Higgins et al.,

. Antibody-mediated, Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients, J Am Soc Nephrol JASN, vol.28, issue.6, pp.1912-1935, 2017.

M. Haas, J. Mirocha, N. L. Reinsmoen, A. A. Vo, J. Choi et al., Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies, Kidney Int, vol.91, issue.3, pp.729-766, 2017.

D. Kumar, M. Raynaud, J. Chang, J. Reeve, I. Yakubu et al., Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection, Transplantation, 2020.

R. F. Parsons, A. Zahid, S. Bumb, H. Decker, H. C. Sullivan et al., The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.20, issue.2, pp.573-81, 2020.

M. J. Pérez-sáez, B. Yu, A. Uffing, N. Murakami, T. J. Borges et al., Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy, Clin Kidney J, vol.12, issue.4, pp.586-91, 2019.

E. Melilli, A. Manonelles, N. Montero, J. Grinyo, A. Martinez-castelao et al., Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?, Clin Kidney J, vol.11, issue.3, pp.413-434, 2018.

R. Leal, D. Tsapepas, R. J. Crew, G. K. Dube, L. Ratner et al., Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation, Kidney Int Rep, vol.3, issue.2, pp.281-90, 2018.

T. Vanhove, R. Goldschmeding, and D. Kuypers, Kidney Fibrosis: Origins and Interventions, Transplantation, vol.101, issue.4, pp.713-739, 2017.

P. T. Jindra, Y. Jin, E. Rozengurt, and E. F. Reed, HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway, J Immunol Baltim Md, vol.180, issue.4, pp.2357-66, 1950.

X. Zhang, N. M. Valenzuela, and E. F. Reed, HLA class I antibody-mediated endothelial and smooth muscle cell activation. Curr Opin Organ Transplant, vol.17, pp.446-51, 2012.

P. F. Halloran, K. S. Famulski, and J. Reeve, Molecular assessment of disease states in kidney transplant biopsy samples, Nat Rev Nephrol, vol.12, issue.9, pp.534-582, 2016.

D. Bertrand, N. Chavarot, P. Gatault, C. Garrouste, N. Bouvier et al., Opportunistic infections after conversion to belatacept in kidney transplantation, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.35, issue.2, pp.336-381, 202001.